1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
- Herold, Nikolas, et al.
(författare)
-
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
- 2017
-
Ingår i: Nature Medicine. - : Springer Science and Business Media LLC. - 1078-8956 .- 1546-170X. ; 23:2, s. 256-263
-
Tidskriftsartikel (refereegranskat)abstract
- The cytostatic deoxycytidine analog cytarabine (ara-C) is the most active agent available against acute myelogenous leukemia (AML). Together with anthracyclines, ara-C forms the backbone of AML treatment for children and adults'. In AML, both the cytotoxicity of ara-C in vitro and the clinical response to ara-C therapy are correlated with the ability of AML blasts to accumulate the active metabolite ara-C triphosphate (ara-CTP)(2-5), which causes DNA damage through perturbation of DNA synthesis(6). Differences in expression levels of known transporters or metabolic enzymes relevant to ara-C only partially account for patient-specific differential ara-CTP accumulation in AML blasts and response to ara-C treatment(7-9). Here we demonstrate that the deoxynucleoside triphosphate (dNTP) triphosphohydrolase SAM domain and HD domain 1 (SAMHD1) promotes the detoxification of intracellular ara-CTP pools. Recombinant SAMHD1 exhibited ara-CTPase activity in vitro, and cells in which SAMHD1 expression was transiently reduced by treatment with the simian immunodeficiency virus (SIV) protein Vpx were dramatically more sensitive to ara-C-induced cytotoxicity. CRISPR-Cas9-mediated disruption of the gene encoding SAMHD1 sensitized cells to ara-C, and this sensitivity could be abrogated by ectopic expression of wild-type (WT), but not dNTPase-deficient, SAMHD1. Mouse models of AML lacking SAMHD1 were hypersensitive to ara-C, and treatment ex vivo with Vpx sensitized primary patient derived AML blasts to ara-C. Finally, we identified SAMHD1 as a risk factor in cohorts of both pediatric and adult patients with de novo AML who received ara-C treatment. Thus, SAMHD1 expression levels dictate patient sensitivity to ara-C, providing proof-of-concept that the targeting of SAMHD1 by Vpx could be an attractive therapeutic strategy for potentiating ara-C efficacy in hematological malignancies.
|
|
8. |
|
|
9. |
- Jonasson, Christian, et al.
(författare)
-
Modelling the effect of different core sizes and magnetic interactions inside magnetic nanoparticles on hyperthermia performance
- 2019
-
Ingår i: Journal of Magnetism and Magnetic Materials. - : Elsevier BV. - 0304-8853 .- 1873-4766. ; 477, s. 198-202
-
Tidskriftsartikel (refereegranskat)abstract
- We present experimental intrinsic loss power (ILP) values, measured at an excitation frequency of 1 MHz and at relatively low field amplitudes of 3.4–9.9 kA/m, as a function of the mean core diameter, for selected magnetic nanoparticles (MNPs). The mean core sizes ranged from ca. 8 nm to 31 nm. Transmission electron microscopy indicated that those with smaller core sizes (less than ca. 22 nm) were single-core MNPs, while those with larger core sizes (ca. 29 nm to 31 nm) were multi-core MNPs. The ILP data showed a peak at core sizes of ca. 20 nm. We show here that this behaviour correlates well with the predicted ILP values obtained using either a non-interacting Debye model, or via dynamic Monte-Carlo simulations, the latter including core-core magnetic interactions for the multi-core particles. This alignment of the models is a consequence of the low field amplitudes used. We also present interesting results showing that the core-core interactions affect the ILP value differently depending on the mean core size.
|
|
10. |
|
|